论文部分内容阅读
过继输入淋巴因子激活的杀伤细胞(L-AK细胞)是肿瘤继承性免疫治疗(AIT)的主要方法,是近几年来肿瘤治疗的一大突破。但由于单独应用LAK细胞疗效欠佳,用大剂量白细胞介素Ⅱ(IL-2)又容易引起严重副作用,故使其临床应用受到一定限
Adoptive delivery of lymphokine-activated killer cells (L-AK cells) is the primary method of adoptive immunotherapy (AIT) in tumors and is a major breakthrough in the treatment of cancer in recent years. However, due to poor efficacy of LAK cells alone, high doses of interleukin 2 (IL-2) are likely to cause serious side effects, so its clinical application has been limited